explore -WSS

explore

author：hotspot 2025-10-01 23:43:27 - browse：8472

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Federal weight loss drug coverage is 30 years out of date

WSS

Death of patient in Alzheimer’s trial raises question of possible risks

Goldman Sachs launches $650M fund for life science investments

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Federal weight loss drug coverage is 30 years out of date

The science behind Janet Jackson's pregnancy at 49

UCB departs biotech trade group BIO

focus

explore

entertainment

Drug repurposing or repositioning? The language matters

Cloning humans is technically possible. It's curious no one has tried

Cancer drug shortages should be causing more outrage

The science behind Janet Jackson's pregnancy at 49

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The story of mRNA: From a loose idea to a tool that may help curb Covid

In age of alternative facts, a scholarly course on calling out crap

How a scoliosis diagnosis changed the life of one young dancer

Anesthesiologist group: stop taking Ozempic before surgery

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

focus

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Do masks work? RCTs can't tell us

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Ahead of JPM, here's who's profiting most in health care

Why drug prescriptions should include diagnoses

New guidelines on severe brain injury complicate already difficult decisions

Wikipedia

Wikipedia

focus

focus